Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by DNB Asset Management AS

DNB Asset Management AS trimmed its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 6.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,194 shares of the biotechnology company’s stock after selling 347 shares during the period. DNB Asset Management AS’s holdings in Sarepta Therapeutics were worth $820,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. GAMMA Investing LLC raised its position in shares of Sarepta Therapeutics by 37.0% in the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 87 shares during the last quarter. Vanguard Capital Wealth Advisors raised its position in shares of Sarepta Therapeutics by 3.8% in the fourth quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock valued at $236,000 after buying an additional 90 shares during the last quarter. Riggs Asset Managment Co. Inc. raised its position in shares of Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 125 shares during the last quarter. WCM Investment Management LLC grew its holdings in shares of Sarepta Therapeutics by 2.3% in the first quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock valued at $813,000 after purchasing an additional 142 shares during the period. Finally, New York Life Investment Management LLC grew its holdings in shares of Sarepta Therapeutics by 1.7% in the fourth quarter. New York Life Investment Management LLC now owns 9,942 shares of the biotechnology company’s stock valued at $959,000 after purchasing an additional 166 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. BMO Capital Markets upped their price objective on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Monday, June 24th. Citigroup lowered shares of Sarepta Therapeutics from a “buy” rating to a “neutral” rating and upped their price objective for the company from $172.00 to $176.00 in a report on Wednesday, June 26th. SVB Leerink upped their price objective on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, June 24th. Needham & Company LLC reissued a “buy” rating and issued a $235.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, June 27th. Finally, Evercore ISI upped their price objective on shares of Sarepta Therapeutics from $139.00 to $185.00 and gave the company an “in-line” rating in a report on Monday, June 24th. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $187.72.

Sarepta Therapeutics Stock Up 0.6 %

Sarepta Therapeutics stock traded up $0.81 during trading on Wednesday, reaching $143.66. The stock had a trading volume of 27,903 shares, compared to its average volume of 1,359,797. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $173.25. The business has a 50 day moving average price of $140.29 and a 200 day moving average price of $131.31. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18. The stock has a market cap of $13.58 billion, a PE ratio of 1,298.64 and a beta of 0.89.

Insider Buying and Selling

In related news, insider Bilal Arif sold 7,859 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the transaction, the insider now owns 21,261 shares in the company, valued at $3,467,243.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Bilal Arif sold 7,859 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the transaction, the insider now owns 21,261 shares in the company, valued at $3,467,243.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Ryan Edward Brown sold 38,957 shares of Sarepta Therapeutics stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the completion of the transaction, the executive vice president now owns 17,129 shares of the company’s stock, valued at approximately $2,768,217.69. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.